Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 161

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Tryptophan metabolism: entering the field of aging and age-related pathologies

van der Goot, Annemieke T., Nollen, Ellen A.A.·2013·Trends in Molecular Medicine

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.molmed.2013.02.007

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Research works printed but not linked: 75

  1. Scully, 2012, Demography: To the limit, Nature, 492, S2, 10.1038/492S2a · DOI
  2. Mair, 2008, Aging and survival: the genetics of life span extension by dietary restriction, Annu. Rev. Biochem., 77, 727, 10.1146/annurev.biochem.77.061206.171059 · DOI · Paper page
  3. Greer, 2009, Different dietary restriction regimens extend lifespan by both independent and overlapping genetic pathways in C. elegans, Aging Cell, 8, 113, 10.1111/j.1474-9726.2009.00459.x · DOI · Paper page
  4. Kenyon, 2010, The genetics of ageing, Nature, 464, 504, 10.1038/nature08980 · DOI · Paper page
  5. Wullschleger, 2006, TOR signaling in growth and metabolism, Cell, 124, 471, 10.1016/j.cell.2006.01.016 · DOI · Paper page
  6. Bjedov, 2010, Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster, Cell Metab., 11, 35, 10.1016/j.cmet.2009.11.010 · DOI · Paper page
  7. Wu, 2002, Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis, Cancer Res., 62, 1030
  8. Morley, 2002, The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans, Proc. Natl. Acad. Sci. U.S.A., 99, 10417, 10.1073/pnas.152161099 · DOI · Paper page
  9. Cohen, 2006, Opposing activities protect against age-onset proteotoxicity, Science, 313, 1604, 10.1126/science.1124646 · DOI · Paper page
  10. Killick, 2009, Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice, Biochem. Biophys. Res. Commun., 386, 257, 10.1016/j.bbrc.2009.06.032 · DOI
  11. Cohen, 2009, Reduced IGF-1 signaling delays age-associated proteotoxicity in mice, Cell, 139, 1157, 10.1016/j.cell.2009.11.014 · DOI · Paper page
  12. Anisimov, 2010, Rapamycin extends maximal lifespan in cancer-prone mice, Am. J. Pathol., 176, 2092, 10.2353/ajpath.2010.091050 · DOI · Paper page
  13. Bove, 2011, Fighting neurodegeneration with rapamycin: mechanistic insights, Nat. Rev. Neurosci., 12, 437, 10.1038/nrn3068 · DOI · Paper page
  14. Stone, 2002, Endogenous kynurenines as targets for drug discovery and development, Nat. Rev. Drug Discov., 1, 609, 10.1038/nrd870 · DOI · Paper page
  15. van der Goot, 2012, Delaying aging and the aging-associated decline in protein homeostasis by inhibition of tryptophan degradation, Proc. Natl. Acad. Sci. U.S.A., 109, 14912, 10.1073/pnas.1203083109 · DOI · Paper page
  16. Oxenkrug, 2010, The extended life span of Drosophila melanogaster eye-color (white and vermilion) mutants with impaired formation of kynurenine, J. Neural Transm., 117, 23, 10.1007/s00702-009-0341-7 · DOI
  17. Schroecksnadel, 2011, Influence of immunosuppressive agents on tryptophan degradation and neopterin production in human peripheral blood mononuclear cells, Transpl. Immunol., 25, 119, 10.1016/j.trim.2011.06.005 · DOI
  18. Kanai, 2009, Tryptophan 2,3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice, Mol. Brain, 2, 8, 10.1186/1756-6606-2-8 · DOI · Paper page
  19. Mellor, 2003, Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion, J. Immunol., 171, 1652, 10.4049/jimmunol.171.4.1652 · DOI · Paper page
  20. Frick, 2004, Increasing production of homocysteine and neopterin and degradation of tryptophan with older age, Clin. Biochem., 37, 684, 10.1016/j.clinbiochem.2004.02.007 · DOI · Paper page
  21. Pertovaara, 2006, Indoleamine 2,3-dioxygenase activity in nonagenarians is markedly increased and predicts mortality, Mech. Ageing Dev., 127, 497, 10.1016/j.mad.2006.01.020 · DOI
  22. Friberg, 2002, Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection, Int. J. Cancer, 101, 151, 10.1002/ijc.10645 · DOI · Paper page
  23. Pilotte, 2012, Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase, Proc. Natl. Acad. Sci. U.S.A., 109, 2497, 10.1073/pnas.1113873109 · DOI · Paper page
  24. Giorgini, 2005, A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease, Nat. Genet., 37, 526, 10.1038/ng1542 · DOI · Paper page
  25. Campesan, 2011, The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease, Curr. Biol., 21, 961, 10.1016/j.cub.2011.04.028 · DOI · Paper page
  26. Zwilling, 2011, Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration, Cell, 145, 864, 10.1016/j.cell.2011.05.020 · DOI · Paper page
  27. Le Floc’h, 2011, Tryptophan metabolism, from nutrition to potential therapeutic applications, Amino Acids, 41, 1195, 10.1007/s00726-010-0752-7 · DOI · Paper page
  28. Yoshida, 1981, Induction of pulmonary indoleamine 2,3-dioxygenase by interferon, Proc. Natl. Acad. Sci. U.S.A., 78, 129, 10.1073/pnas.78.1.129 · DOI · Paper page
  29. Hayaishi, 1978, Specific induction of pulmonary indoleamine 2,3-dioxygenase by bacterial lipopolysaccharide, Ciba Found. Symp., 65, 199
  30. Guillemin, 2001, Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection, J. Neurochem., 78, 842, 10.1046/j.1471-4159.2001.00498.x · DOI · Paper page
  31. Fukui, 1991, Blood–brain barrier transport of kynurenines: implications for brain synthesis and metabolism, J. Neurochem., 56, 2007, 10.1111/j.1471-4159.1991.tb03460.x · DOI · Paper page
  32. Pfefferkorn, 1984, Interferon γ blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan, Proc. Natl. Acad. Sci. U.S.A., 81, 908, 10.1073/pnas.81.3.908 · DOI · Paper page
  33. Gupta, 1994, Antiparasitic and antiproliferative effects of indoleamine 2,3-dioxygenase enzyme expression in human fibroblasts, Infect. Immun., 62, 2277, 10.1128/IAI.62.6.2277-2284.1994 · DOI
  34. MacKenzie, 1999, Growth inhibition of multiresistant enterococci by interferon-γ-activated human uro-epithelial cells, J. Med. Microbiol., 48, 935, 10.1099/00222615-48-10-935 · doi:10.1099/00222615-48-10-935
  35. Munn, 1998, Prevention of allogeneic fetal rejection by tryptophan catabolism, Science, 281, 1191, 10.1126/science.281.5380.1191 · DOI · Paper page
  36. Mellor, 2001, Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy, Nat. Immunol., 2, 64, 10.1038/83183 · DOI · Paper page
  37. Munn, 2007, Indoleamine 2,3-dioxygenase and tumor-induced tolerance, J. Clin. Invest., 117, 1147, 10.1172/JCI31178 · DOI · Paper page
  38. Munn, 1999, Inhibition of T cell proliferation by macrophage tryptophan catabolism, J. Exp. Med., 189, 1363, 10.1084/jem.189.9.1363 · DOI · Paper page
  39. Lee, 2002, Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division, Immunology, 107, 452, 10.1046/j.1365-2567.2002.01526.x · DOI · Paper page
  40. Rohde, 2001, The TOR kinases link nutrient sensing to cell growth, J. Biol. Chem., 276, 9583, 10.1074/jbc.R000034200 · DOI · Paper page
  41. Gao, 2002, Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling, Nat. Cell Biol., 4, 699, 10.1038/ncb847 · DOI · Paper page
  42. Zhang, 2002, The GCN2 eIF2α kinase is required for adaptation to amino acid deprivation in mice, Mol. Cell. Biol., 22, 6681, 10.1128/MCB.22.19.6681-6688.2002 · DOI · Paper page
  43. Harding, 2000, Regulated translation initiation controls stress-induced gene expression in mammalian cells, Mol. Cell, 6, 1099, 10.1016/S1097-2765(00)00108-8 · DOI · Paper page
  44. Munn, 2005, GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase, Immunity, 22, 633, 10.1016/j.immuni.2005.03.013 · DOI · Paper page
  45. Fallarino, 2006, The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells, J. Immunol., 176, 6752, 10.4049/jimmunol.176.11.6752 · DOI · Paper page
  46. Fallarino, 2002, T cell apoptosis by tryptophan catabolism, Cell Death Differ., 9, 1069, 10.1038/sj.cdd.4401073 · DOI · Paper page
  47. Frumento, 2002, Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase, J. Exp. Med., 196, 459, 10.1084/jem.20020121 · DOI · Paper page
  48. Terness, 2002, Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites, J. Exp. Med., 196, 447, 10.1084/jem.20020052 · DOI · Paper page
  49. Wirleitner, 2003, Immune activation and degradation of tryptophan in coronary heart disease, Eur. J. Clin. Invest., 33, 550, 10.1046/j.1365-2362.2003.01186.x · DOI · Paper page
  50. Niinisalo, 2008, Indoleamine 2,3-dioxygenase activity associates with cardiovascular risk factors: the Health 2000 study, Scand. J. Clin. Lab. Invest., 68, 767, 10.1080/00365510802245685 · DOI
  51. Pedersen, 2011, Systemic markers of interferon-γ-mediated immune activation and long-term prognosis in patients with stable coronary artery disease, Arterioscler. Thromb. Vasc. Biol., 31, 698, 10.1161/ATVBAHA.110.219329 · DOI
  52. Lob, 2009, Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?, Nat. Rev. Cancer, 9, 445, 10.1038/nrc2639 · DOI · Paper page
  53. Platten, 2012, Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion, Cancer Res., 72, 5435, 10.1158/0008-5472.CAN-12-0569 · DOI · Paper page
  54. Stone, 2013, An expanding range of targets for kynurenine metabolites of tryptophan, Trends Pharmacol. Sci., 34, 136, 10.1016/j.tips.2012.09.006 · DOI · Paper page
  55. Savvateeva, 2000, Age-dependent memory loss, synaptic pathology and altered brain plasticity in the Drosophila mutant cardinal accumulating 3-hydroxykynurenine, J. Neural Transm., 107, 581, 10.1007/s007020070080 · DOI
  56. Widner, 1999, Degradation of tryptophan in neurodegenerative disorders, Adv. Exp. Med. Biol., 467, 133, 10.1007/978-1-4615-4709-9_19 · DOI
  57. Widner, 2000, Tryptophan degradation and immune activation in Alzheimer's disease, J. Neural Transm., 107, 343, 10.1007/s007020050029 · DOI · Paper page
  58. Pearson, 1992, Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease, Neurosci. Lett., 144, 199, 10.1016/0304-3940(92)90749-W · DOI
  59. Guidetti, 2000, Early kynurenergic impairment in Huntington's disease and in a transgenic animal model, Neurosci. Lett., 283, 233, 10.1016/S0304-3940(00)00956-3 · DOI
  60. Guidetti, 2006, Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice, Neurobiol. Dis., 23, 190, 10.1016/j.nbd.2006.02.011 · DOI · Paper page
  61. van Ham, 2008, C. elegans model identifies genetic modifiers of α-synuclein inclusion formation during aging, PLoS Genet., 4, e1000027, 10.1371/journal.pgen.1000027 · DOI · Paper page
  62. Kimura, 1997, daf-2, an insulin receptor-like gene that regulates longevity and diapause in Caenorhabditis elegans, Science, 277, 942, 10.1126/science.277.5328.942 · DOI · Paper page
  63. Kenyon, 1993, A C. elegans mutant that lives twice as long as wild type, Nature, 366, 461, 10.1038/366461a0 · DOI · Paper page
  64. Friedman, 1988, A mutation in the age-1 gene in Caenorhabditis elegans lengthens life and reduces hermaphrodite fertility, Genetics, 118, 75, 10.1093/genetics/118.1.75 · DOI · Paper page
  65. Clancy, 2001, Extension of life-span by loss of CHICO, a Drosophila insulin receptor substrate protein, Science, 292, 104, 10.1126/science.1057991 · DOI · Paper page
  66. Tatar, 2001, A mutant Drosophila insulin receptor homolog that extends life-span and impairs neuroendocrine function, Science, 292, 107, 10.1126/science.1057987 · DOI · Paper page
  67. Bluher, 2003, Extended longevity in mice lacking the insulin receptor in adipose tissue, Science, 299, 572, 10.1126/science.1078223 · DOI · Paper page
  68. Jia, 2004, The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span, Development, 131, 3897, 10.1242/dev.01255 · DOI · Paper page
  69. Honjoh, 2009, Signalling through RHEB-1 mediates intermittent fasting-induced longevity in C. elegans, Nature, 457, 726, 10.1038/nature07583 · DOI · Paper page
  70. Wang, 2009, TOR-mediated autophagy regulates cell death in Drosophila neurodegenerative disease, J. Cell Biol., 186, 703, 10.1083/jcb.200904090 · DOI
  71. Kapahi, 2004, Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway, Curr. Biol., 14, 885, 10.1016/j.cub.2004.03.059 · DOI · Paper page
  72. Luong, 2006, Activated FOXO-mediated insulin resistance is blocked by reduction of TOR activity, Cell Metab., 4, 133, 10.1016/j.cmet.2006.05.013 · DOI · Paper page
  73. Miller, 2011, Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice, J. Gerontol. A: Biol. Sci. Med. Sci., 66, 191, 10.1093/gerona/glq178 · DOI · Paper page
  74. Anisimov, 2011, Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice, Cell Cycle, 10, 4230, 10.4161/cc.10.24.18486 · DOI · Paper page
  75. Muller, 2008, Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase, Proc. Natl. Acad. Sci. U.S.A., 105, 17073, 10.1073/pnas.0806173105 · DOI · Paper page

Cited by

See all 161

Metadata

Authors
van der Goot, A. T., & Nollen, E. A. A.
Venue
Trends in Molecular Medicine
Publisher
Elsevier BV
Published
2013-06
Volume
19
Issue
6
Pages
336-344
ISSN
1471-4914 (ISSN-L)
OpenAlex
W1971400022
Cited by
161
References
17
FWCI
1.03
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tryptophan metabolism: entering the field of aging and age-related pathologies. https://app.cochat.ai/papers/10.1016/j.molmed.2013.02.007
The paper
van der Goot, A. T., & Nollen, E. A. A. (2013). Tryptophan metabolism: entering the field of aging and age-related pathologies. Trends in Molecular Medicine. https://doi.org/10.1016/j.molmed.2013.02.007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.